MLYS · Mineralys Therapeutics, Inc.
$25.64
-0.45 (-1.72%)
At close · Aug 14
Market Cap
$2.27B
Shares
88.41M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$25.64
Open$25.88
Day$25.42–25.89
52W close$14.13–47.33
Avg vol 30d762K
Short int9.3M · 10.5% float · 15.1d
Short vol48%
Last earningsAug 11, 2026
DataFeb 2023–Aug 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 13, 2026
Est · unconfirmed
· in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−17%
below
Price vs 50-day avg
−3%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
35%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−5%
trailing
6-month return
−11%
trailing
YTD return
−29%
this year
Relative strength
−25%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $26 › 200d $31 — 200d above 50d
Institutional flow
Accumulating
+4% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.53% of float · ▼ -2.5% MoM · 15.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
225 holders — near 3-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
EPS growth
+37%
Y/Y
Balance sheet
$172.9M
net cash
Quant / Vol
risk profile
Volatility
105%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−17%
Bearish
Price vs 50-day avg
−3%
Neutral
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
35%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $26 › 200d $31 — 200d above 50d
Institutional flow
Accumulating
+4% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.53% of float · ▼ -2.5% MoM · 15.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
225 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $14
Now $26 · 35%
Range high $47
vs 200-day avg -17%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MLYS
this stock
Mineralys Therapeutics, Inc.
|
$2.27B | -29.3% | — | — | 10.5% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MLYS | -6.3% | -5.4% | -11.4% | +0.5% | -29.4% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -6.7% | -9.8% | -25.1% | -3.5% | -43.2% |
Key facts
CIK
1933414
CUSIP
603170101
13F (30d)
219 filings
217 filers
Visit website
Investor relations